Abbott Laboratories (ABT) vs Amylyx Pharmaceuticals, Inc. (AMLX)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| ABT | AMLX | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Drug Manufacturers - Specialty & Generic |
| Size band | LARGE | MID |
| Listing | NYSE | Nasdaq GS |
| Country | United States | United States |
| Theme | medical-devices | rare-disease |
| Price and returns | ||
| Last close | $104.88 | $27.09 |
| Return · 1 week | +0.79% | −0.88% |
| Return · 1 month | +3.86% | −9.25% |
| Return · 3 months | −2.23% | +38.57% |
| Return · year to date | −14.59% | +137.22% |
| Return · 1 year | −16.60% | +90.37% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −20.56% | −34.15% |
| 52-week high | $132.03 | $41.14 |
| 52-week low | $81.97 | $10.83 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $182.68B | $3.40B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $816.81M | $37.98M |
| Employees | 122,000 | 136 |
| Valuation | ||
| Price to earnings · trailing | 33.84× | n/a (negative earnings) |
| Price to earnings · forward | 17.29× | n/a (negative forward earnings) |
| Price to sales | 3.92× | — |
| Price to book | 3.55× | 12.66× |
| Enterprise value to EBITDA | 17.92× | n/a (negative value) |
| Enterprise value to revenue | 4.49× | — |
| PEG ratio | 1.92 | — |
| Earnings per share · trailing | 3.10 | -1.41 |
| Profitability | ||
| Gross margin | 56.61% | — |
| Operating margin | 14.71% | 0.00% |
| Profit margin | 11.59% | — |
| Return on equity | 10.58% | −74.73% |
| Return on assets | 5.33% | −44.13% |
| Growth | ||
| Revenue growth | +13.00% | — |
| Earnings growth | −47.50% | — |
| Balance sheet and payout | ||
| Debt / equity (%) | 63.21 | 2.20 |
| Current ratio | 1.38 | 12.12 |
| Dividend yield | 2.40% | 0.00% |
| Payout ratio | 78.71% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 57.14 | 42.23 |
| ADX · 14 | 20.25 | 20.77 |
| 50-day average | $105.04 | $31.31 |
| 200-day average | $102.11 | $19.77 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 2.75% | 5.11% |
The full ABT analysis
Everything this table leaves out for Abbott Laboratories: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the ABT argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full ABT analysisThe full AMLX analysis
Everything this table leaves out for Amylyx Pharmaceuticals, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the AMLX argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full AMLX analysis